Efficacy and safety of metformin or oral contraceptives, or both in polycystic ovary syndrome

Therapeutics and Clinical Risk Management

Volumn 11, Issue , 2015, Pages 1345-1353

  Yang, Young Mo ^a   Choi, Eun Joo ^a  

^a Chosun University   (South Korea)

Author keywords

Efficacy; Hyperandrogenism; Metformin; Oral contraceptive pill; Ovulatory dysfunction; Polycystic ovary syndrome; Safety

Indexed keywords

CYPROTERONE ACETATE PLUS ETHINYLESTRADIOL; DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORGESTIMATE; INSULIN; METFORMIN; ORAL CONTRACEPTIVE AGENT; PLACEBO; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

BODY MASS; COMBINATION CHEMOTHERAPY; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HEADACHE; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; MENORRHAGIA; MONOTHERAPY; NAUSEA; OBESITY; OVARY POLYCYSTIC DISEASE; PROTEIN BLOOD LEVEL; REVIEW; SYSTEMATIC REVIEW; TESTOSTERONE BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

EID: 84940773516     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S89737     Document Type: Review

References (38)

1. Domecg JP, Prutsky G, Mullan RJ, et al. Adverse effects of the com­mon treatments for polycystic ovary syndrome: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2013;98(12):4646–4654.
2. Johnson NP. Metformin use in women with polycystic ovary syn­drome. Ann Transl Med. 2014;2(6):56. doi: 10.3978/j.issn.2305–5839.2014.04.15.
3. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2013;6:1–13.
4. Setji TL, Brown AJ. Polycystic ovary syndrome: update on diagnosis and treatment. Am J Med. 2014;127(10):912–919.
5. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syn­drome. In: Givens JHF, Merriman G, editors. The Polycystic Ovary Syndrome. Cambridge, MA: Blackwell Scientific; 1992:377–384.
6. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25.
7. Azziz R, Carmina E, Dewailly D, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab. 2006;91(11):4237–4245.
8. Saha L, Kaur S, Saha PK. Pharmacotherapy of polycystic ovary syndrome – an update. Fundam Clin Pharmacol. 2012;26(1):54–62.
9. Peigne M, Dewailly D. Long term complications of polycystic ovary syndrome (PCOS). Ann Endocrinol (Paris). 2014;75(4):194–199.
10. Glintborg D, Altinok ML, Mumm H, Hermann AP, Ravn P, Andersen M. Body composition is improved during 12 months’ treat­ment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. J Clin Endocrinol Metab. 2014;99(7):2584–2591.
11. Conway G, Dewailly D, Diamanti-Kandarakis E, et al. The polycystic ovary syndrome: a position statement from the European society of endocrinology. Eur J Endocrinol. 2014;171(4):P1–P29.
12. Morin-Papunen L, Vauhkonen L, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syn­drome: a randomized study. J Clin Endocrinol Metab. 2003;88(1):148–156.
13. Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. Eur J Endocrinol. 2005;152(2):269–275.
14. Mitkov M, Pehlivanov B, Terzieva D. Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2005;118(2):209–213.
15. Soares GM, Vieira CS, de Paula Martins W, Dos Reis RM, de Sa MF, Ferriani RA. Metabolic and cardiovascular impact of oral contraceptives in polycystic ovary syndrome. Int J Clin Pract. 2009;63(1):160–169.
16. Lopez LM, Edelman A, Chen M, Otterness C, Trussell J, Helmerhorst FM. Progestin-only contraceptives: effects on weight. Cochrane Database Syst Rev. 2013;7:CD008815. doi: 10.1002/14651858.CD008815.pub3.
17. Kaminski P, Szpotanska-Sikorska M, Wielgos M. Cardiovascular risk and the use of oral contraceptives. Neuro Endocrinol Lett. 2013;34(7):587–589.
18. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contracep­tives and risk of venous thrombosis: meta-analysis. BMJ. 2001;323(7305):131–134.
19. Essah PA, Arrowood JA, Cheang KI, Adawadkar SS, Stovall DW, Nestler JE. Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertil Steril. 2011;96(2):501–504.
20. Panidis D, Georgopoulos NA, Piouka A, et al. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperan­drogenemia. Gynecol Endocrinol. 2011;27(8):587–592.
21. Bilgir O, Kebapcilar L, Taner C, et al. The effect of ethinylestradiol (EE)/cyproterone acetate (CA) and EE/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS). Intern Med. 2009;48(14):1193–1199.
22. Elter K, Imir G, Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod. 2002;17(7):1729–1737.
23. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab. 2000;85(9):3161–3168.
24. Homburg R. Polycystic ovary syndrome – from gynaecological curiosity to multisystem endocrinopathy. Hum Reprod. 1996;11(1):29–39.
25. Linneke JL, Jorgensen GK, Csillag C. Metformin for weight loss and control in patients with mood disorder. J Clin Psychiatry. 2014;75(10):e1140–e1141.
26. Bjorkhem-Bergman L, Asplund AB, Lindh JD. Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis. J Psychopharmacol. 2011;25(3):299–305.
27. Jensterle Sever M, Kocjan T, Pfeifer M, Kravos NA, Janez A. Short-term combined treatment with liraglutide and metformin leads to sig­nificant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol. 2014;170(3):451–459.
28. Nieuwenhuis-Ruifrok AE, Kuchenbecker WK, Hoek A, Middleton P, Norman RJ. Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis. Hum Reprod Update. 2009;15(1):57–68.
29. Pau CT, Keefe C, Duran J, Welt CK. Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study. J Clin Endocrinol Metab. 2014;99(5):1870–1878.
30. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82(2):524–530.
31. Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistant and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol. 1998;138(3):269–274.
32. Domecg JP, Prutsky G, Mullan RJ, et al. Lifestyle modification programs in polycystic ovary syndrome: systemic review and meta-analysis. J Clin Endocrinol Metab. 2013;98(12):4655–4663.
33. Nasri H, Rafieian-Kopaei M. Metformin: current knowledge. J Res Med Sci. 2014;19(7):658–664.
34. Lalau JD. Lactic acidosis induced by metformin: incidence, management and prevention. Drug Saf. 2010;33(9):727–740.
35. Scheen AJ. Metformin and lactic acidosis. Acta Clin Belg. 2011;66(5):329–331.
36. Brynhildsen J. Combined hormonal contraceptives: prescribing patterns, compliance, and benefits versus risks. Ther Adv Drug Saf. 2014;5(5):201–213.
37. Dragoman MV. The combined oral contraceptive pill-recent develop­ments, risk and benefits. Best Pract Res Clin Obstet Gynaecol. 2014;28(6):825–834.
38. Yildiz BO. Approach to the patient: contraception in women with polycys­tic ovary syndrome. J Clin Endocrinol Metab. 2015;100(3):794–802.